Europe Digital Therapeutics Market By End Use, By Applications, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

The Europe Digital Therapeutics Market is expected to witness market growth of 21.3% CAGR during the forecast period (2021-2027).

Digital therapeutics is a term that refers to a section of digital health, which is a software driven evidence-based intervention. There is a lot of potential in digital therapeutics to fulfil the unfulfilled requirements of patients, which traditional treatments & therapies could not fulfil. Thus, organizations that are using life science technologies to fill the gap between demand & supply of healthcare solutions along with faster product development is expected to get more advantages than traditional life sciences enterprises.

Several companies across the industries are getting inspired and keen to explore the potential of the digital therapeutics market. Some technology giants are also planning to enter and transform the healthcare sector. Players are keen to know how digital therapeutics affect reimbursement policies and simultaneously exploring the way patient data collected via these products can be utilized to inform coverage. A few of the start-ups are also launching unique concepts to attract more investors.

Healthcare facilities across the world have a huge cost involved; many people could not afford a basic healthcare facility, which created the need for the solutions which can reduce healthcare costs. Digital therapeutics assist in decreasing the costs incurred in chronic diseases, by assisting patients or an insurance provider to monitor a person’s health status and also track it with the help of digital solutions. The cost of treatment of chronic diseases like diabetes has increased over the years. This increasing cost is expected to be managed well by using digital therapeutics that is available by the providers to assist in managing diabetes. Digital therapeutics can help people in getting assistance for disease management and face the logistical challenges unwrapped by the doctors.

The Germany market dominated the Europe Respiratory Diseases Applications Market by Country 2020, thereby, achieving a market value of $109.9 million by 2027. The UK market is exhibiting a CAGR of 22.8% during (2021 - 2027). Additionally, The France market is poised to grow at a CAGR of 24.5% during (2021 - 2027).

Based on End Use, the market is segmented into Patients, Providers, Payers, Employers and Others. Based on Applications, the market is segmented into Diabetes, CNS Disease, Respiratory Diseases, Smoking Cessation, Obesity, CVD and others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ResMed, Inc. (Propeller Health), Teladoc Health, Inc. (Livongo Health), Noom, Inc., Omada Health, Inc., Welldoc, Inc., Canary Health, Mango Health, Inc. (TrialCard, Incorporated), 2Morrow, Inc., Pear Therapeutics, Inc., and Mindstrong, Inc.

Scope of the Study

Market Segments covered in the Report:

By End Use

• Patients
• Providers
• Payers
• Employers
• Others

By Application

• Diabetes
• CNS Disease
• Respiratory Diseases
• Smoking Cessation
• Obesity
• CVD
• others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• ResMed, Inc. (Propeller Health)
• Teladoc Health, Inc. (Livongo Health)
• Noom, Inc.
• Omada Health, Inc.
• Welldoc, Inc.
• Canary Health
• Mango Health, Inc. (TrialCard, Incorporated)
• 2Morrow, Inc.
• Pear Therapeutics, Inc.
• Mindstrong, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free